See more : PPG Industries, Inc. (PPG) Income Statement Analysis – Financial Results
Complete financial analysis of Summit Therapeutics Inc. (SMMT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Summit Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PHX Minerals Inc. (PHX) Income Statement Analysis – Financial Results
- Hotai Finance Co., Ltd. (6592.TW) Income Statement Analysis – Financial Results
- Linius Technologies Limited (LNU.AX) Income Statement Analysis – Financial Results
- Bonraybio Co., Ltd. (6955.TWO) Income Statement Analysis – Financial Results
- Eidai Kako Co.,Ltd. (7877.T) Income Statement Analysis – Financial Results
Summit Therapeutics Inc. (SMMT)
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 704.30K | 1.81M | 860.00K | 632.02K | 56.41M | 35.98M | 2.88M | 0.00 | 2.27M | 2.27M | 2.87M | 2.77M | 1.21M | 301.95K | 266.64K | 6.03M | 2.03M | 947.89K | 212.76K | 1.82K |
| Cost of Revenue | 2.05M | 2.51M | 0.00 | 0.00 | 155.40K | 24.92K | 97.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 5.77K | 2.51M | 596.30K | 415.93K | 169.46K | 1.82K |
| Gross Profit | -2.05M | -1.81M | 1.81M | 860.00K | 476.62K | 56.39M | 35.88M | 2.88M | 0.00 | 2.27M | 2.27M | 2.87M | 1.77M | 1.21M | 301.95K | 260.87K | 3.51M | 1.43M | 531.96K | 43.31K | 0.00 |
| Gross Profit Ratio | 0.00% | -256.95% | 100.00% | 100.00% | 75.41% | 99.96% | 99.73% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 63.68% | 100.00% | 100.00% | 97.84% | 58.28% | 70.60% | 56.12% | 20.35% | 0.00% |
| Research & Development | 59.47M | 52.00M | 85.35M | 53.27M | 32.71M | 51.38M | 41.01M | 23.69M | 23.94M | 15.64M | 10.83M | 5.72M | 4.78M | 3.66M | 3.68M | 7.38M | 15.34M | 5.79M | 1.83M | 504.60K | 0.00 |
| General & Administrative | 30.27M | 26.70M | 23.61M | 19.23M | 7.24M | 16.19M | 16.98M | 10.35M | 7.45M | 6.80M | 3.24M | 2.77M | 2.31M | 2.68M | 3.83M | 3.91M | 5.14M | 863.07K | 1.79M | 75.31K | 43.79K |
| Selling & Marketing | -2.05M | 0.00 | 0.00 | 0.00 | 2.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 372.24K | 1.12M | 2.17M | 1.00M | 0.00 | 0.00 | 0.00 |
| SG&A | 28.22M | 26.70M | 23.61M | 19.23M | 9.30M | 16.19M | 16.98M | 10.35M | 7.45M | 6.80M | 3.24M | 2.77M | 2.31M | 2.68M | 4.20M | 5.03M | 7.31M | 1.86M | 1.79M | 75.31K | 43.79K |
| Other Expenses | 0.00 | -14.42M | -20.97M | -19.31M | 0.00 | -19.88M | -3.86M | -1.95M | -3.14M | -682.90K | -682.90K | 18.95K | 339.19K | -10.32M | 3.48M | 2.97M | 2.70M | 2.37M | 119.60K | 0.00 | -1.82K |
| Operating Expenses | 87.69M | 64.28M | 88.00M | 53.19M | 42.00M | 47.69M | 54.13M | 33.94M | 29.45M | 19.29M | 13.33M | 8.51M | 7.45M | 5.55M | 9.49M | 15.43M | 26.92M | 10.03M | 3.74M | 579.92K | 43.79K |
| Cost & Expenses | 89.74M | 64.28M | 88.00M | 53.19M | 43.40M | 47.69M | 54.13M | 33.94M | 29.45M | 19.29M | 13.33M | 8.51M | 7.45M | 5.55M | 9.49M | 15.43M | 29.43M | 10.62M | 4.16M | 749.37K | 45.61K |
| Interest Income | 10.40M | 1.51M | 178.95K | 4.00K | 4.34K | 3.66M | 4.38M | 10.00K | 30.00K | 0.00 | 14.85K | 17.37K | 10.99K | 26.90K | 12.78K | 430.95K | 1.54M | 1.72M | 1.04M | 404.81K | 1.82K |
| Interest Expense | 16.46M | 4.40M | 281.00K | 255.00K | 32.52K | 556.10K | 1.65M | 1.08M | 0.00 | 448.00K | 0.00 | 0.00 | 4.71K | 6.33K | 107.04K | 116.74K | 75.56K | 11.77K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 90.74M | 2.51M | 2.46M | 2.00M | 1.39M | 1.49M | 348.21K | 72.50K | 68.36K | 49.72K | 42.89K | 146.89K | 295.22K | 710.54K | 3.78M | 2.74M | 3.28M | 737.53K | 240.99K | 9.41K | 1.82K |
| EBITDA | 1.00M | -52.63M | -62.74M | -37.13M | -16.80M | 11.66M | -32.19M | -30.98M | -20.30M | -12.20M | -11.02M | -5.48M | -4.41M | -8.65M | -5.41M | -16.03M | -18.58M | -6.13M | -2.97M | -527.20K | -41.96K |
| EBITDA Ratio | 0.00% | -8,633.17% | -4,764.29% | -5,985.47% | -6,546.15% | 24.59% | -37.31% | -1,075.82% | 0.00% | -854.30% | -486.04% | -191.35% | -157.79% | -298.82% | -1,786.78% | -4,499.47% | -308.42% | -302.42% | -203.69% | -57.52% | -2,300.00% |
| Operating Income | -89.74M | -72.09M | -86.19M | -53.19M | -42.76M | 12.38M | -18.25M | -31.07M | -28.73M | -19.15M | -11.07M | -7.23M | -4.71M | -9.38M | -9.20M | -19.20M | -23.40M | -8.60M | -3.21M | -536.61K | -43.79K |
| Operating Income Ratio | 0.00% | -10,235.63% | -4,764.29% | -6,185.23% | -6,766.39% | 21.95% | -50.73% | -1,078.69% | 0.00% | -844.40% | -487.93% | -252.32% | -170.09% | -777.06% | -3,047.63% | -7,198.94% | -388.45% | -423.79% | -338.91% | -252.21% | -2,400.00% |
| Total Other Income/Expenses | -526.14M | -19.15M | -24.87M | -14.01M | -1.04M | -3.30M | 1.91M | -854.00K | 5.54M | -427.00K | 14.85K | 17.37K | 6.28K | 20.57K | -94.26K | 314.20K | 1.47M | 1.71M | 1.04M | 404.81K | 1.82K |
| Income Before Tax | -615.87M | -78.78M | -88.60M | -52.91M | -28.41M | 6.60M | -15.42M | -32.13M | -28.69M | -19.07M | -11.05M | -7.21M | -4.71M | -9.36M | -9.30M | -18.88M | -21.94M | -6.88M | -2.17M | -131.80K | -41.96K |
| Income Before Tax Ratio | 0.00% | -11,185.94% | -4,897.84% | -6,152.33% | -4,494.86% | 11.70% | -42.85% | -1,115.76% | 0.00% | -841.02% | -487.27% | -251.71% | -169.86% | -775.36% | -3,078.84% | -7,081.10% | -364.13% | -339.36% | -229.12% | -61.95% | -2,300.00% |
| Income Tax Expense | -946.00K | -4.40M | -2.46M | -213.00K | -4.52M | -3.27M | -5.32M | -5.42M | -4.36M | -1.95M | -1.00M | -538.61K | -477.37K | -1.94M | -594.31K | -2.52M | -1.81M | -959.18K | -278.48K | -45.19K | -1.82K |
| Net Income | -614.93M | -74.38M | -86.15M | -52.70M | -23.88M | 9.87M | -10.09M | -26.71M | -24.34M | -17.12M | -10.05M | -6.67M | -4.23M | -7.42M | -8.66M | -32.29M | -20.13M | -5.92M | -1.89M | -86.61K | -41.96K |
| Net Income Ratio | 0.00% | -10,561.06% | -4,762.13% | -6,127.56% | -3,779.08% | 17.50% | -28.05% | -927.56% | 0.00% | -754.85% | -443.13% | -232.91% | -152.63% | -614.68% | -2,867.20% | -12,109.76% | -334.06% | -292.07% | -199.74% | -40.71% | -2,300.00% |
| EPS | -0.99 | -0.38 | -0.93 | -0.76 | -0.15 | 0.11 | -0.16 | -0.43 | -0.41 | -0.43 | -2.08 | -0.42 | -0.02 | -0.04 | -0.13 | -0.60 | -0.42 | -0.16 | -0.06 | 0.00 | 0.00 |
| EPS Diluted | -0.99 | -0.38 | -0.93 | -0.76 | -0.15 | 0.11 | -0.15 | -0.43 | -0.41 | -0.43 | -2.08 | -0.42 | -0.02 | -0.04 | -0.13 | -0.60 | -0.42 | -0.16 | -0.06 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 619.65M | 193.34M | 92.24M | 69.52M | 164.15M | 86.14M | 65.03M | 61.55M | 59.10M | 39.60M | 4.83M | 15.81M | 177.88M | 166.29M | 67.01M | 53.39M | 47.90M | 36.42M | 31.31M | 23.47M | 19.02M |
| Weighted Avg Shares Out (Dil) | 619.65M | 193.34M | 92.24M | 69.52M | 164.15M | 86.14M | 65.43M | 61.55M | 59.10M | 39.60M | 4.83M | 15.81M | 177.88M | 166.29M | 67.01M | 53.39M | 47.90M | 36.42M | 31.31M | 23.47M | 19.02M |
Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide
NPMA decision on whether to approve Summit Therapeutics Inc.'s ivonescimab for the treatment of patients with EGFR-mutant metastatic non-squamous NSCLC following TKI progression is expected in Q2 of 2024.
Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman of the Board and Chief Executive Officer Maky Zanganeh -...
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Operational & Corporate Updates Our operational progress...
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the...
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. “We are excited to add Dr. Ronaghi to complement our excellent group...
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually April 16-17, 2024. Dr. Maky Zanganeh, Chief...
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor
Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics' executive Ankur Dhingra.
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO , April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced...
Why Summit Therapeutics Stock Crushed the Market This Week
An analyst initiated coverage of Summit Therapeutics with an enthusiastic buy recommendation. He feels its investigational cancer drug has vast potential.
Source: https://incomestatements.info
Category: Stock Reports